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Available online 26 April 2004Over the past decade, many publications have described Historical measurements of plasmaexperiments in which the recombinant monomeric form of
the gp120 surface envelope (Env) glycoprotein of human
immunodeficiency virus type 1 (HIV-1) has been added to
cells in vitro (Fig. 1). The ensuing cellular responses (e.g.,
activation of signal transduction pathways resulting in
cytokine release, chemotaxis, proliferation, anergy, or apo-
ptosis) are monitored. The outcome is generally that gp120
can kill a target cell or perturb its normal functions, and it is
assumed that what is observed in vitro is relevant in vivo.
Our intent is to question whether such an extrapolation is
reasonable on quantitative grounds, particularly when the
presence of antibodies (Abs) in the plasma of HIV-1-
infected persons is taken into account. We cite only a small
selection from this abundant literature, to illustrate the range
of active gp120 concentrations reported.
In the in vitro experiments, the gp120 concentrations
vary from 1 pM to 1 AM (ca. 0.12 ng/ml to 120 Ag/ml, as 1
nMc 0.12 Ag/ml, e.g. Arthos et al., 2002; Chirmule et al.,
1990; Davis et al., 1997; Esser et al., 2001; Goldman et al.,
1994; Herbein et al., 1998; Hesselgesser et al., 1998; Huang
et al., 2001; Kanmogne et al., 2001; Keswani et al., 2003;
Kornfeld et al., 1988; Mann et al., 1987; Masci et al., 2003;
Munshi et al., 2003; Oyaizu et al., 1990; Schneider-Schau-
lies et al., 1992; Tamma et al., 1997; Vlahakis et al., 2003;
Wahl et al., 1989; Weinhold et al., 1989; Weissman et al.,
1997; Yao et al., 2001). Sometimes biological effects occur
only at the higher end of the range, although particularly in
neuronal cell systems lower gp120 concentrations can be
active. In those systems, the primary effects may be partly
on microglial cells, which are reported to amplify secondary
effects on neurons (cf. Garden, 2002; Kaul and Lipton,
1999; Keswani et al., 2003, reviewed in Kaul et al., 2001).0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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Two papers are usually cited to suggest that the gp120
concentrations used in vitro resemble those in body fluids,
specifically plasma (Gilbert et al., 1991; Oh et al., 1992).
Our impression is that these papers are often either cited
incorrectly or misunderstood. What do they, in fact, report?
Oh et al. detected gp120 in a majority of AIDS patients’ sera
in the range 0.1–0.8 nM. No gp120 was found in the sera of
HIV-1-infected individuals with AIDS-related complex
(ARC). Thus, only in sera from people at the late clinical
stages of infection, when HIV-1 antigen levels tend to rise,
was free gp120 ever, apparently, detectable. However,
gp120 in complex with antibody (Ab) was found in a larger
proportion of sera, a point to which we shall return. In
contrast, Gilbert et al. (2003) detected gp120 only in the
range 2–20 pM, and then only in a minority of sera from
p24-antigenemic AIDS and ARC patients. The plasma
gp120 concentrations detected by Oh et al. were thus one
to two orders of magnitude higher than those described by
Gilbert et al. (2003). Hence, the two papers should not be
cited as agreeing with each other.
Both papers rely on capture enzyme-immunoassays to
quantify gp120. The assay of Gilbert et al. (2003) uses a
soluble form of CD4, the primary receptor for gp120 (see
Fig. 1), to capture gp120 onto a solid phase. The bound
gp120 is then detected with a polyclonal sheep Ab raised
against a peptide from the C terminus of gp120 of the T-cell
line-adapted isolate IIIB. This antibody, D7324, cross-reacts
strongly with gp120s from multiple HIV-1 strains, particu-
larly within subtype B but also outside it (Moore and Jarrett,
1988; Moore et al., 1994b). As soluble CD4 is pan-reactive
with properly folded gp120s, the assay used by Gilbert et al.
(2003) is relatively little affected by gp120 sequence diver-
sity. In contrast, Oh et al. employed a polyclonal serum to
gp120 of the IIIB isolate for capture, with a monoclonal Ab
(MAb) to the V3 loop of IIIB gp120 as the detection
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provided, but it is stated ‘‘to have 10–15% cross-reactivity
with other strains’’. Regardless of whether this value refers
to the extent of binding or the proportion of test gp120s that
it reacted with, it is now well understood that the recognition
of gp120 from primary viruses by IIIB-specific V3-loopMAbs is usually poor. The cross-reactivity capabilities of
the assay used by Oh et al., and hence its ability to detect
and quantify gp120 in plasma, is, therefore, questionable at
best. This assay would be expected to underestimate plasma
gp120 content by failing to recognize gp120 from the
infecting strain. However, its results suggest that gp120 is
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relative to what was found by Gilbert et al. (2003) and to
viremia, as discussed below.
A related issue, approached by Oh et al. and addressed
more directly by Gilbert et al. (2003), is that of interference
by plasma antibodies. Gilbert et al. (2003) found that mixing
gp120 with control human serum significantly decreased the
subsequent signal and that high titers of HIV-1+ sera could
abrogate the signal completely. One of us (J.P.M.) observed
much the same effect in unpublished experiments many
years ago, using a capture enzyme immunoassay based on
Ab D7324 and a polyclonal anti-gp120 serum. Thus, when a
known amount of gp120 was spiked into different HIV-1+
sera, the anti-gp120 Abs present interfered significantly with
gp120 detection, and to an extent that varied greatly
between the sera. Indeed, it was impossible to judge from
the assay readout what amount of gp120 had been added to
the different HIV-1+ sera. Therefore, any estimation of how
much gp120 was naturally present in the HIV-1+ sera was
clearly problematic. The same concerns apply to p24
antigen quantification in the presence of plasma anti-p24
antibodies: only when immune complexes are dissociated,
for example by the use of heat, can p24 concentrations be
properly determined (Schupbach and Boni, 1993).
Taken together, the uncertainty about the efficiency of
gp120 capture, the extent of cross-reactivity of the detecting
Abs with any gp120 present in plasma (at least in the assay
used by Oh et al.), and the interference by plasma anti-gp120
Abs, all but preclude any accurate estimate of plasma gp120
concentrations by the methods that have been used to date. Of
note is that Gilbert et al. (2003) found no correlation between
plasma p24 and gp120 concentrations, which may reflect
differences in the extent of Ab complexing with the two
antigens. The limitations of the published assays need to be
taken into account when these papers are cited, particularly in
respect of the high gp120 concentrations reported by Oh et al.Alternative estimates of plasma gp120 concentrations
What concentrations of gp120 could be expected in HIV-
1+ plasma? Plasma concentrations of the viral Gag protein
(Fig. 1) p24 provide a useful guide. Most plasma p24 antigen
is normally Ab-complexed or virion-associated. But after its
release as a free protein, it is detected at concentrations <40Fig. 1. (a) The HIV-1 envelope glycoprotein (Env) complex consists of trimers o
gp120, anchored to a transmembrane protein gp41, which is involved in the fusion
(left) interacting with the four-domain receptor, CD4. This binding induces a confo
CCR5 for R5 virus and CXCR4 for X4 virus (right). The interactions of gp120 w
gp120 is shown to undergo interactions corresponding to those in (a). This scheme
gp120. A significant degree of binding and many experimental effects are only obt
in extracellular fluids in vivo (top). A complex between gp120 and soluble CD4
CD4, the affinity of gp120 for CCR5 or CXCR4 is low (bottom, left). Specific a
downstream contact with the coreceptor (bottom, right). The blocking effect of
concentration is lower, such as the central nervous system. (c) An HIV-1 virion is s
the phospholipid bilayer that surrounds the viral Gag proteins and RNA genome.pM (Ledergerber et al., 2000), that is, just above the 2–20 pM
reported for free gp120 by Gilbert et al. (2003). If virions
were the only source, gp120 concentrations would be 40- to
60- fold lower than those of p24 (Chertova et al., 2002; Layne
et al., 1992; Zhu et al., 2003). It can be calculated that a
plasma viral load of 106 virions/ml—a high level for chronic
HIV-1 infection—corresponds to only 0.03–0.07 pM of
virion-associated gp120 and 2–3 pM p24. While this con-
centration of virion-associated p24 is somewhat below the
upper range of total p24 in plasma (Ledergerber et al., 2000),
this gp120 concentration is between two (Gilbert et al., 1991)
and four (Oh et al., 1992) orders of magnitude lower than the
often cited values.
Gp120 that is not associated with virions could potentially
be derived from infected cells. The envelope glycoprotein
complex (Fig. 1) is produced and processed via the secretory
pathway, whereas the Gag precursor is synthesized on free
ribosomes in the cytoplasm. Although virions incorporate
approximately 50-fold fewer Env than Gag molecules when
they bud from cellular membranes (see Fig. 1c) (Chertova et
al., 2002), we do not know the ratio of Gag to Env in infected
cells in vivo. It could be argued that the majority of Env never
exits from the secretory pathway, and that significant addi-
tional amounts of gp120 is released from dead or moribund
cells as ‘‘viral debris’’ (Parren et al., 1997). However, some of
this debris would not interact with receptors and such lysed
cells would also release p24. Hence, it is hard to explain how
gp120 proteins capable of receptor binding could be present
at higher concentrations than p24.The effect of plasma antibodies on gp120–receptor
interactions
We noted above that plasma anti-gp120 Abs mask the
detection and quantification of gp120. The same antibodies
have a very significant effect on the receptor interactions of
any gp120 that is present in plasma. Abs to gp120 are
usually present at high enough concentrations in plasma to
bind up most of the gp120 present. The ratio [Ab]/Kd
determines their degree of binding to gp120, in accordance
with the law of mass action (Klasse and Sattentau, 2002).
Anti-gp120 Ab concentrations have been estimated to be in
the micromolar range (Binley et al., 1997); so for high-
affinity binding (Kd < 10 nM), the occupancy of gp120 byf non-covalently linked heterodimers of an outer, receptor-binding moiety,
of the viral envelope with the cell membrane. The gp120 moiety is shown
rmational change that facilitates the interaction of gp120 with a coreceptor,
ith CCR5 and CXCR4 are weak in the absence of CD4. (b) A monomer of
is reproduced in many experiments making use of monomeric recombinant
ained at much higher concentrations than what could realistically be present
is shown to interact with a coreceptor on the cell surface. In the absence of
ntibodies prevent gp120 from binding to CD4; this also precludes further,
antibodies is likely to occur in vivo except in certain tissues where their
hown schematically. The Env trimers of heterodimers (gp120 and gp41) stud
The copy-number ratio of the Gag to Env in virions is f50.
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to inhibit the binding of gp120 to CD4 (and hence indirectly
to CCR5 or CXCR4) are in the range 1:100 to 1:1000 in
HIV-1+ sera (Callahan and Norcross, 1989; Moore et al.,
1994a). Thus, in the presence of undiluted HIV-1+ plasma,
as occurs in vivo, there would be effectively no binding of
gp120 monomers to CD4 or the co-receptors. This is rarely
accounted for in the design and interpretation of in vitro
studies with recombinant gp120, but it always should be.
Less complexing of gp120 by Abs would occur in some
tissue locales. For example, Abs are present only at low levels
in the central nervous system, even when HIV-1 infection
causes intrathecal Ab production and blood–brain barrier
leakage (Goudsmit et al., 1987; Kaul et al., 2001). In general,
Ab concentrations in different tissues are likely to vary
considerably from those of gp120 and virus. Predicting the
net effects of variations in relative and absolute concentra-
tions of Ab, gp120 and virus is a complex task that we do not
attempt here.Concentration of gp120 in tissues
The putative levels of gp120 measured, or plausibly
present, in plasma are far below some of those that have
significant effects on cells in vitro. But could the latter
concentrations nevertheless be biologically relevant by
matching those in compartments other than blood? The
gp120 concentrations in, for example, the interstitial spaces
of lymph nodes or other solid organs are unknown. Never-
theless, if the greater density of cells, the smaller extracel-
lular space and the possibly slower dilution kinetics were
quantitatively factored in, it seems plausible that gp120
could be present within interstitial lymph node spaces at
concentrations several orders of magnitude higher than in
plasma. Furthermore, if small secluded spaces are created
during cell-to-cell transmission of HIV-1 and HTLV-1, the
so-called virological synapses (Igakura et al., 2003; Jolly et
al., 2004), then viral proteins may be present at high local
concentrations in those clefts. In vitro studies involving
Env-producing cells may, therefore, be more realistic than
those using soluble, recombinant gp120 (Castedo et al.,
2001, 2002; Jekle et al., 2003). However, the gp120
concentration gradients produced by such cells are difficult
to assess. And membrane-associated Env may differ from
soluble gp120 in, for example, its qualitative effects on T-
cell activation (Schwartz et al., 1994).
Another relevant complication is that gp120 from X4
viruses, but not R5 viruses, binds to heparan-sulphate
glycosoaminoglycan (GAG) moieties of proteoglycans,
and thereby can be retained within tissues both in the
extracellular matrix and on cell surfaces (Moulard et al.,
2000; Ugolini et al., 1999). GAGs are present on the surface
of many cell types (Ugolini et al., 1999). An analogy may
be drawn between gp120 and chemokines that, in vivo, do
not seem to act as free proteins. Chemokines, instead,interact with G-protein-coupled receptors while in the form
of surface-bound GAG complexes that establish haptotactic
gradients in tissues (Proudfoot et al., 2003). Such potentially
modulating effects of the tissue environment complicate the
rational design and interpretation of in vitro experiments,
which by necessity simulate in vivo conditions imperfectly.
We conclude that the relevant gp120 concentrations in
the organism are essentially unknown.Affinity of gp120 for its receptors and the influence of
receptor occupancy
Ultimately, any consequences of local concentrations of
gp120 depend on its affinity for the relevant receptors and
the degree of binding required for signals to be transduced.
Several effects of gp120 are mediated through CD4 binding,
either directly or indirectly through subsequent CD4-depen-
dent interactions with a chemokine coreceptor. The Kd of
gp120 binding to CD4 is in the range 1–10 nM (Ashkenazi
et al., 1990; Ivey-Hoyle et al., 1991; Moebius et al., 1992;
Moore, 1990). That is higher even than the concentrations
reported by Oh et al. and 1000-fold higher than those found
by Gilbert et al. (2003). However, gp120 may also bind with
high affinity to DC-SIGN and other C-type lectin receptors
(Geijtenbeek et al., 2002; Turville et al., 2002), as well as to
the GAG moieties of proteoglycans (Moulard et al., 2000;
Ugolini et al., 1999). Although the latter interactions of
soluble monomeric X4 gp120 are readily reversible (Mon-
dor et al., 1998b), binding to such accessory attachment
molecules could raise the effective gp120 concentrations
available for other receptor interactions.
Quite distinct degrees of binding, or occupancies, of
cellular receptors may be required to exert the different
effects on the target cells that we are discussing. But gener-
ally, the occupancy can be estimated from the formula
[[gp120]/Kd]/[[1 + [gp120]]/Kd] (Klasse and Moore, 1996).
Thus, for 99% occupancy, the concentration of gp120 must
be >100-fold above Kd. That means 0.1–1 AM for CD4
binding. Indirect effects of gp120 on T-cell activation, medi-
ated by blocking the interactions of antigen-MHC class II
with CD4 and the T-cell receptor (Chirmule et al., 1995),
would quite plausibly require the binding of gp120 to a large
proportion of CD4 molecules. Some effects involving sig-
naling via cell-surface receptors are, in principle, different.
Thus, much lower occupancies, produced by gp120 concen-
trations close to or below Kd (Munshi et al., 2003) could
conceivably be effective. Most biological effects would
nevertheless require a detectable occupancy. Hence, we face
a double conundrum: either active concentrations of gp120
are above Kd for receptor binding, which may not be realistic
under in vivo conditions; or they are lower, which makes it
difficult to explain how substantial binding could be
achieved.
Some effects of gp120 are suggested to occur indepen-
dently of CD4 (for example, Iyengar et al., 1999). The
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CD4 is usually found to fall below the limit of detection.
Thus, there was no detectable X4 gp120 binding to CXCR4
at concentrations as high as 0.25–0.5 AM (Doranz et al.,
1999; Mondor et al., 1998a), and little binding of R5 gp120
to CCR5 at 0.4–0.5 AM (Trkola et al., 1996; Wu et al.,
1996). There is, however, one starkly contrasting report of
higher-affinity gp120 binding (Kd c 70 nM) to CXCR4 on
CD4-negative, differentiated neuronal cells (Hesselgesser et
al., 1997). The binding of soluble-CD4–gp120 complexes
to CCR5 has a Kd off4 nM (Doranz et al., 1999; Wu et al.,
1996), and to CXCR4 off200 nM (Babcock et al., 2001).
Despite the poor or controversial capacity of gp120 to
interact directly with CCR5 or CXCR4, a pathophysiolog-
ical role for the interaction of gp120 with these molecules
on neurons and astrocytes has been proposed (Kaul et al.,
2001). If the highest reported gp120–CXCR4 affinity is
accurate (Hesselgesser et al., 1997), then the dose depen-
dence of X4 gp120-mediated apoptotic effects via CXCR4
on CD4 neuronal cells is as expected, that is, a significant
and increasing response from 20 nM to 1 AM (Hesselgesser
et al., 1998). But whether that extremely high concentration
range is relevant in vivo remains to be confirmed. In
contrast, much lower concentrations of gp120 (0.1–200
pM) have also been found to be neurotoxic, with and
without intermediary effects on Schwann and glial cells
(Keswani et al., 2003; Meucci et al., 1998). The occupancy
of CXCR4 at gp120 concentrations in the sub-nanomolar
range would be immeasurably low (<0.1%), even if we
assume that the Kd c 70 nM (Hesselgesser et al., 1997).
It is possible to investigate whether gp120 is bound to
cells from HIV-1-infected individuals, and at what occupan-
cy, ex vivo. The presence of gp120 attached to CD4 on the
T-cell surface ex vivo has been inferred, although not
directly detected (Amadori et al., 1992). But there is also
a converse finding of the failure to detect specific masking
of the gp120-binding site on CD4 on T cells from HIV-1-
infected individuals (Kunkl et al., 1994). Resolving whether
gp120 is detectable on the surface of CD4+ (or CD4) cells
ex vivo would help clarify gp120’s pathogenic role.
The outstanding task, then, is to assess and explain the
occupancy of receptors by gp120 in vivo and what effects
that has on the cells.Use of virions in vitro
Some in vitro experiments have used virus-like particles
or inactivated virions to study HIV-1-induced apoptosis, for
comparison with the effects of recombinant soluble gp120
(Esser et al., 2001; Vlahakis et al., 2003; Yao et al., 2001).
When virus for this use is concentrated by several orders of
magnitude, considerations apply that are similar to those for
monomeric gp120: how well does the virion concentration
used in vitro reflect what is present in vivo? Can virion
densities rise to particularly high levels in certain locales,such as interstitial spaces in lymph nodes, and there exert the
effects observed in vitro? The affinity of virions for target
cells is unknown but liable to be the net outcome of two
opposing influences. The receptor-interactive surfaces on the
gp120 subunits are relatively inaccessible in the context of
the virion-associated Env trimer, which will reduce the
functional affinity of the interaction. Countering this, is the
polyvalency effect of multiple trimers interacting with mul-
tiple receptors (as partly illustrated for murine leukemia
virus; Yu et al., 1995). The binding of X4 virions to heparan
sulphate proteoglycans on the cell surface is indeed more
avid than that of monomeric gp120 (Mondor et al., 1998b).
Inactivated virus with a content of 0.4 nM of p24 (Esser et
al., 2001), or even as high as 4 nM (Vlahakis et al., 2003), has
been used in vitro. This corresponds to f8–80 pM virion-
associated gp120. The degree of receptor binding that may
ensue at these levels of virion-associated Env cannot be
rationally predicted at present. But the maximal virus-in-
duced apoptotic effect could not be mimicked by the
corresponding amounts of monomeric gp120 or heat-dena-
tured virions, and it required the presence of MHC class II on
the virion (Esser et al., 2001). However, in another experi-
mental system, HIV-1-induced cytolysis occurred regardless
of the presence of MHC class II (LaBonte et al., 2003).
Cytolysis is an alternative mechanism of cell death to induced
by receptors, and cytolysis are alternative mechanisms of cell
death, cytolysis requires fusogenic Env protein, and affects
only the infected cell (LaBonte et al., 2003).
The relative relevance of the experimental use of soluble
Env, inactivated virions and fusogenic replicating virus to
the pathogenesis of AIDS needs to be elucidated.Improving the design of experiments using gp120
How could the design of in vitro studies using monomeric
gp120 be improved (see box)? The possible presence of
biologically active contaminants, including endotoxins in
gp120 preparations from commercial and other sources
should always be considered. The use of anti-gp120 MAbs
specifically to prevent gp120-CD4 or -coreceptor binding is a
prudent control. As noted above, HIV-1+ serum antibodies
will havemuch the same effect as the specificMAbs, and their
presence in vivo must be taken into account. Gp120 point
mutants defective for CD4 or coreceptor binding provide
further controls. Thereby one can at least determine whether
the consequences of sprinkling gp120 on mammalian cells
depend on receptor binding, or whether they are merely
attributable to contaminants in the protein preparation.Conclusions
We do not argue that gp120 could never have a biological
effect on cells in vivo via receptor-mediated interactions.
Nor is it impossible that virions could influence cellular
P.J. Klasse, J.P. Moore / Virology 323 (2004) 1–86processes in vivo independently of receptor-mediated fusion
events.
We do, however, argue that it is not an adequate mimic of
in vivo biology simply to add free gp120 (or virions) to
target cells in vitro in amounts that are apparently several
orders of magnitude greater than in body fluids. Moreover, it
is not appropriate to justify the amounts of gp120 used by
reference to the two decade-old papers that purport to
measure free gp120 in the plasma of HIV-1-infected people.
These papers are not consistent with each other, and the
more frequently cited study, by Oh et al., has serious design
flaws that may cast doubt on the gp120 concentrations it
promulgates. The much lower gp120 concentrations
recorded by Gilbert et al. (2003) are likely to be closer to
true levels. And the presence of plasma anti-gp120 Abs that
block receptor binding should inform the design of in vitro
experiments (see Box 1). Controls for gp120 purity and forBox 1. Criteria for establishing the biological
relevance of experiments using gp120 in vitro
1. Experimental concentration ranges shown to be
relevant to the particular tissue compartment
modeled.
2. Specificity of the receptor interactions demonstrated
by use of gp120 deletion mutants or Abs blocking
receptor binding.
3. Demonstration that the requisite receptor occu-
pancy can be obtained under experimental con-
ditions.
4. Inclusion of anti-gp120 Abs with a binding capacity
(concentration and affinity) corresponding to that in
the relevant tissue compartment.
5. Comparison of effects of recombinant gp120 with
those of realistic levels of virions.the specificity of the interactions with CD4, chemokine
receptors and GAGs should also be included in experimen-
tal protocols. Some of these considerations apply, of course,
to other studies of similar design that use high concentra-
tions of other HIV-1 proteins, such as Tat and Vpr, in vitro,
in the hope that this is relevant to pathogenesis.Acknowledgments
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